DESCRIPTION

Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

IMPACT FACTOR

2019: 3.558 © Clarivate Analytics Journal Citation Reports 2020

ABSTRACTING AND INDEXING

PubMed/Medline  
Scopus  
Directory of Open Access Journals (DOAJ)

EDITORIAL BOARD

Co-Editors-in-Chief

Bushra Ateeq, Indian Institute of Technology Kanpur, Kanpur, India  
Genetic/epigenetic alterations in prostate cancer, Cancer Biomarkers and Drug Targets, Mechanism of Drug resistance, non-coding RNAs in cancer.

Justin Durla Lathia, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, United States  
Caroline E. Nunes-Xavier, Radium Hospital Institute for Cancer Research, Oslo, Norway  
Immune checkpoint proteins, Immunotherapy, Protein tyrosine phosphatase,

Günter Schneider, Technical University of Munich Hospital Rechts der Isar, München, Germany

Vivek Subbiah, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States  
Yu Sun, Shanghai Institutes for Biological Sciences Chinese Academy of Sciences, Shanghai, China  
Cancer Resistance, Tumor Microenvironment, Cellular Senescence, Aging and Age-related diseases

Verna D.N.K. Vanderpuye, Korle Bu Teaching Hospital, National Radiotherapy Oncology and Nuclear Medicine, Accra, Ghana  
Radiology, Oncology and Radiotherapy

Jun Yan, University of Louisville School of Medicine, Louisville, Kentucky, United States
International Advisory Board

Katherine Aird, University of Pittsburgh, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Cancer metabolism, cellular senescence, ovarian cancer, epigenetics, DNA damage response

Kambiz N. Alavian, Imperial College London, London, United Kingdom
Neurodegeneration, Parkinson's disease, Cancer, brain tumors, Glioma, Mitochondria.

Geoffroy Andrieux, University Medical Center Freiburg, Institute of Medical Bioinformatics and Systems Medicine, Freiburg, Germany
Bioinformatics, Systems Medicine, Next Generation Sequencing

Alberto Anel, University of Zaragoza, Zaragoza, Spain
Cytotoxicity, cell death, cancer immunotherapy

Mohammad Asim, University of Surrey Department of Clinical and Experimental Medicine, Guildford, United Kingdom
Cancer molecular biology, prostate cancer, androgen receptor, nuclear hormone receptor

Tony Avril, Eugene Marquis Cancer Institute, Rennes, France
Brain tumor, ER stress, IRE1 signaling, cancer stem cells, tumor invasion/migration, immunosuppression

Christian E. Badr, Harvard Medical School, Massachusetts General Hospital, Boston, United States
Brain tumors, Neurooncology

Pedro C. Barata, Tulane University, New Orleans, Louisiana, United States
Genitourinary tumors - prostate cancer, kidney cancer, bladder cancer; clinical trials, immunotherapy

Jared Barrott, Idaho State University, Pocatello, Idaho, United States
Sarcomas, Epigenetics, Precision Medicine

Defne Bayik, Cleveland Clinic, Cleveland, Ohio, United States
Cancer immunotherapy, myeloid cells, immunosuppression TLR signalling

Edgar Ben-Josef, Ruth and Raymond Perelman Center for Advanced Medicine, Philadelphia, Pennsylvania, United States

James A. Bonner, The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center, Birmingham, Alabama, United States

Corrine Bousquet, Cancer Research Center of Toulouse, Toulouse, France
Tumor Microenvironment

Jan Brábek, Charles University, Prague, Czech Republic
Cancer cell invasiveness and migration, integrin-mediated signaling

Dean Brenner, University of Michigan, Ann Arbor, Michigan, United States

David N Brindley, Cancer Research Institute of Northern Alberta, University of Alberta, Edmonton, Alberta, Canada
Role of lipid mediators and inflammation in cancer progression and treatment by chemotherapy and radiotherapy with special interests in autotaxin, lysosphotatidic acid, lipid phosphate phosphatases

Kara Britt, Peter MacCallum Cancer Centre, Melbourne, Australia
Breast cancer cell biology, breast stem cells, hormonal regulation of cancer risk, microenvironment and cancer

James P. Brody, University of California Davis Biomedical Engineering Department, Sacramento, California, United States
Cancer genetic risk scores, cancer big data, computational science in cancer

Jan C Buckner, Mayo Clinic Rochester, Rochester, Minnesota, United States

Roberta Buono, University of California Irvine, Irvine, California, United States
Fasting, Cancer, Immunology

Jian Cao, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Fasting, Cancer, Immunology

Qi Cao, Northwestern University, Evanston, Illinois, United States
Epigenetics, miRNA, IncRNA, histone modifications, RNA modifications, prostate cancer, breast cancer, signal transduction

Karen-Sue Carlson, Versiti Blood Research Institute Milwaukee, Milwaukee, Wisconsin, United States
Hematopoiesis, leukemia, myelodysplastic syndrome, myeloproliferative disorders, fibrinolysis

Natalia Castaño-Rodríguez, University of New South Wales, Sydney, New South Wales, Australia
Immunogenetics, gastrointestinal cancer, microbiome

Peiwei Chai, Shanghai Jiao Tong University, Shanghai, China
Ocular malignancies(retinoblastoma, uveal melanoma), long non-coding RNAs(IncRNAs), genetic testing, RNA modifications(m6A, m5C, m1A)

Sayan Chakraborty, Institute of Molecular and Cell Biology, Singapore, Singapore
Tumor microenvironment, tumor angiogenesis, liver cancer, Hippo pathway, the extracellular matrix in cancer, mechanotransduction in cancer, cancer reprogramming, cancer cell signaling, targeted therapies

Sampurna Chatterjee, Harvard Medical School, Boston, Massachusetts, United States
Immuno-Oncology, Pediatric and adult brain cancers, Lung cancer, Tumor microenvironment, molecular signaling, targeted therapy

Ioulia Chatzistamou, University of South Carolina, Columbia, South Carolina, United States
Breast cancer pathology, cytokines and metastasis, animal models of cancer, colon cancer and metabolism

Hui-Zi Chen, OHIO STATE UNIVERSITY, Columbus, Ohio, United States
Genomics, molecular biology, cell biology, small cell lung cancer, GI cancers

Sidi Chen, Yale University, New Haven, Connecticut, United States
Genetics, genomics, immunology, gene editing, CRISPR, cancer, cancer immunology, CAR-T, cell therapy, gene therapy

James C. S Chim, University of Hong Kong, Hong Kong, Hong Kong
Myeloma, Lymphoma, Epigenetics, DNA Methylation

Kin-Hoe Chow, Boston Children's Hospital, Boston, Massachusetts, United States
Oncology, Breast cancer, Pancreatic cancer, Cancer Biomarkers, Metalloproteases, Tumor angiogenesis, Tumor microenvironment, Obesity-associated cancer, Tumor dormancy

Norman C. Coleman, National Institute of Health, Yerevan, Armenia

Fabio Conforti, European Institute of Oncology, Milan, Italy
Breast Cancer, Lung Cancer, Rare Tumors, biomarkers and molecular mechanisms of resistance of targeted therapies

Joseph N. Contessa, Yale Cancer Center, New Haven, Connecticut, United States

Mhairi Copland, University of Glasgow, Glasgow, Scotland, United Kingdom
Myeloid malignancies, leukaemia stem cells, clinical trials, acute leukaemia

Piero Crespo, Institute of Biomedicine and Biotechnology of Cantabria, Santander, Spain
Spatial regulation of RAS-ERK signals in cancer

Nisha D'Silva, University of Michigan Department of Internal Medicine, Ann Arbor, Michigan, United States
Pathology and cancer biology, head and neck cancers, tumor-microenvironment interactions

Juanjuan Dai, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Pancreatic cancer, pancreatitis, tumor microenvironment, microRNA, gut microbiota

Theodore DeWeese, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Hematology, Immuno-Oncology, Stem cell, Therapeutic antibody drug discovery, Signaling transduction

Nabil Djouder, Spanish National Cancer Research Centre, Madrid, Spain
Liver and intestinal diseases, cancer, metabolism, endocrinophysics

Kenneth Dornfeld, University of Minnesota, Minneapolis, Minnesota, United States

Raymond Dubois, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States
Pankaj Dwivedi, AbbVie Inc, North Chicago, Illinois, United States
Cancer Biology, Protein Biochemistry, Proteomics, Phosphoproteomics, Hematology/Oncology, Data Science, Biological Mass Spectrometry

Avraham Eisbruch, University of Michigan, Ann Arbor, Michigan, United States

Deilson Elgui de Oliveira, Sao Paulo State University Julio de Mesquita Filho - Botucatu Campus, BOTUCATU, Brazil
Viral carcinogenesis, Tumor virology, Epstein-Barr Virus, Kaposis Sarcoma Herpesvirus, Epithelial-Mesenchymal Transitions (EMT), Cancer Stem Cells (CSC), Tumor progression, Cancer metastasis

Moshe Elkahets, Ben-Gurion University of the Negev, Be’er Sheva, Israel
Cancer therapy, immunotherapy, head and neck cancer biology, signalling PI3K and MAPK pathways

Eric Fearon, University of Michigan, Ann Arbor, Michigan, United States
Gene silencing, beta-catenin (B-catenin), basic helix-loop-helix transcription factor (bHLH), microRNA (miRNA), colon cancer, epigenetics, Ras protein, tumor marker, breast cancer, E2F transcription factor, Wnt pathway, tumor suppressor gene, p53, oncogene, transcription repressor

Peiwen Fei, University of Hawaii'i Cancer Center, Honolulu, Hawaii, United States
Cancer Biology (tumor suppressors, oncogenes, DNA damage responses, cell cycle, cell death)

Fernando Gianfrancesco, National Research Council of Italy, Bari, Italy
Bone tumors, skeletal diseases, diseases predisposing to bone tumors

Shom Goel, Peter MacCallum Cancer Centre, Melbourne, Australia
Breast Cancer, Cell Cycle Biology, Cancer Epigenetics

Kylie L Gorringe, Peter MacCallum Cancer Centre, Melbourne, Australia
Cancer genomics, Ovarian cancer, Breast cancer, Biomarkers, Organoids

Humaira Gowher, Purdue University Department of Biochemistry, West Lafayette, Indiana, United States
Epigenetics

Barbara T. Grünwald, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada
Tumor Microenvironment, Pancreatic Cancer, Metastasis, Functional Genetic Models

Feda H. Hamdan, Mayo Clinic Rochester, Rochester, Minnesota, United States
Pancreatic cancer, gene transcription regulation, epigenetics and Integrative Bioinformatics

Daniel Hayes, University of Michigan, Ann Arbor, Michigan, United States

Daniel Herranz, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Leukemia, Mouse Models of Cancer, Long-Range Transcriptional Regulation, Cancer Metabolism

Elisabeth Hessmann, University Medical Center Goettingen, Department of Gastroenterology and gastrointestinal Oncology, Göttingen, Germany

Pancreatic cancer, transcription, chromatin regulation

Hubert Hondermarck, The University of Newcastle, Newcastle, New South Wales, Australia

Cancer neurobiology, cancer-nerve crosstalk, neurotrophic growth factors, proteomics

Lucas A. Horn, National Cancer Institute, Bethesda, Maryland, United States

Tumor immunology/immunotherapy, tumor microenvironment, epithelial-mesenchymal transition, MDSC

Peng Hou, Xi’an Jiaotong University Medical College First Affiliated Hospital, Xian, China

Cancer Biology; Targeted therapy; Epigenetics

Christopher G. Hubert, Cleveland Clinic, Cleveland, Ohio, United States

Brain tumors, Glioblastoma, Cancer stem cells, 3D culture, organoids

Ignacio varela, University of Cantabria, Santander, Spain

Cancer Genomics, Next-generation sequencing, chromatin remodelling

Juan L Iovanna, Cancer Research Centre Marseille, Marseille, France

Pancreatic cancer (genetics, transcriptomics, proteomics, personal treatments, molecular and cellular biology), preclinical studies

Sankar Jagadeeshan, Ben-Gurion University of the Negev, Be’er Sheva, Israel

Drug resistance mechanism, molecular oncology, cell signaling, translational medicine, cancer chemoprevention, in vitro and in vivo models, immunotherapy

Mingjie Jiang, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Pancreatic cancer, radiotherapy, tumor microenvironment, tumor recurrence, non-coding RNA

Jin Juan, Fudan University Shanghai Cancer Center, Shanghai, China

Breast Cancer, Immunotherapy,DNA Damage Response

Murugan Kalimutho, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia

Breast and colorectal cancer, cell cycle, cell signaling, DNA damage repair, targeted therapy, resistance

Salma Kaochar, Baylor College of Medicine, Houston, Texas, United States

Prostate cancer, racial disparities in prostate cancer

Manuel Kaulich, Goethe University Frankfurt, Frankfurt am Main, Germany

Gene editing, genetic screening, cell and cancer biology

Wan Hang Keith Chiu, The University of Hong Kong, Pokfulam Road, Hong Kong

Gastrointestinal imaging, Oncological imaging, PET, Artificial Intelligence and Machine Learning

Francesca Khani, Weill Cornell Medicine, New York, New York, United States

Urologic pathology, breast pathology

Thomas Kietzmann, University of Oulu Faculty of Biochemistry and Molecular Medicine, OULU, Finland

Hypoxia, Hypoxia-inducible factors, Redox biology, reactive oxygen species, Liver, Hepatocytes, Cancer metabolism, Antioxidants, Kinase signalling, proteasome, proteasome inhibitors, ubiquitin ligases, protein degradation

Maximilian Kordes, Karolinska Institute, Stockholm, Sweden

Pancreatic cancer, gastric and GEJ cancer, biliary tract cancers, circulating nucleic acids, extracellular vesicles, early clinical trials

Donald Kufe, Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Elena Kuzmin, Rosalind and Morris Goodman Cancer Research Centre, Montréal, Quebec, Canada

Cancer Genomics, Cancer Genetics, Functional Genomics, Yeast Genetics, Genetic Networks

Ezio Laconi, University of Cagliari, Cagliari, Italy

Cancer biology, liver patophysiology, regenerative medicine, aging

El-Nasir Lalani, Aga Khan University, Karachi, Pakistan

Pancreatic cancer, gastric and GEJ cancer, biliary tract cancers, circulating nucleic acids, extracellular vesicles, early clinical trials

Eric Lam, Imperial College London, London, United Kingdom

Transcription; Chromatin; Signalling Cancer, DNA damage response, Drug resistance.

Frederick F. Lang, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States

Sara Laudato, UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, Houston, Texas, United States

Cancer Biology, Cell Biology, Molecular Genetics, Therapy Resistance

Charalampos Lazaris, Whitehead Institute for Biomedical Research, Cambridge, Massachusetts, United States

Nuclear Organization, Transcriptional Regulation, Cancer Epigenetics, Hematological malignancies, Pediatric Cancer

Dung-Fang Lee, University of Texas Health Science Center at Houston, Houston, Texas, United States

iPSC disease model, osteosarcoma

Monika Lewinska, University of Copenhagen, Copenhagen, Denmark
Metabolomics, 'omics' integration, liver cancer, metabolic stress, metabolic associated fatty liver disease, tumor microenvironment

C Ling, Memorial Sloan Kettering Cancer Center, New York, United States

Ines Lohse, University of Miami, Coral Gables, Florida, United States

Drug development, Drug screening, pancreatic cancer, sarcoma, AML, epigenetics

Ashiq Masood, Rush University Medical Center, Chicago, Illinois, United States

Gastrointestinal Oncology, Cancer Genomics, Bioinformatics, precision oncology and clinical trials

Ramsay McFarlane, North West Cancer Research, Liverpool, United Kingdom

Cancer testis antigens / germ line genes in cancer; genome stability in cancer; RNA interference and associated pathways in cancer; retrotransposons in cancer; centromeres and heterochromatin in cancer; chromatin

John Minna, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, Dallas, Texas, United States

Masoud Mozafari, University of Toronto, Toronto, Ontario, Canada

Nanomedicine; Biomaterials; Advanced delivery systems; Translational medicine; Tissue engineering

Jibran Sualeh Muhammad, University of Sharjah, Sharjah, United Arab Emirates

Cancer Biology and Epigenetics

William G. Nelson, Johns Hopkins University, Baltimore, Maryland, United States

Zeribe C. Nwosu, University of Michigan, Ann Arbor, Michigan, United States

Cancer Biology, Metabolism, Genomics, Novel Target Discovery

Shyam Nyati, University of Michigan, Ann Arbor, Michigan, United States

Cancer biology, signal transduction, Assay development, molecular imaging, molecular biology, biochemistry

Fortunato Orazio, Foundation IRCCS National Cancer Institute, Milan, Italy

microRNA, lung cancer and extracellular vesicles

Sandra Ortiz-Cuaron, Cancer Research Centre Lyon, Lyon, France

Drug resistance, Drug tolerance, Liquid Biopsies, ctDNA, Lung cancer, Head and Neck Cancer

Nallasivam Palanisamy, Henry Ford Health System, Department of Urology, Detroit, United States

Cancer Genomics, Molecular Pathology, Prostate Cancer, Molecular Cytogenetics, Tumor heterogeneity

Janani Panneerselvam, The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

Immuno-Oncology, Tumor immunosuppressive microenvironment, Cancer therapeutics, Exosomes and Cancer prevention and drug development

Bjoern Papke, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

RAS oncogenes and RAS-driven cancers such as PDAC, LUAD, CRC; GTPases; Signaling networks; Drug resistance; Single-cell biology; Advanced light microscopy; Organoid models

Haeseong Park, Washington University in St Louis, Saint Louis, Missouri, United States

GI cancer, gastroesophageal cancer, early phase clinical trials

Eileen Parkes, University of Oxford, Oxford, United Kingdom

Cancer immunology, STING dna repair

Harvey I. Pass, NYU LANGONE MEDICAL CENTER, New York, New York, United States

Guangyong Peng, Saint Louis University School of Medicine, Saint Louis, Missouri, United States

Immune metabolism; cell aging; TLR signaling; tumor vaccine; T cell subsets in the tumor microenvironment

Yong Peng, Sichuan University West China Hospital, Chengdu, China

Epigenetics, circular RNA, long noncoding RNA, miRNA

Roberto Carmagnani Pestana, Albert Einstein Israelite Hospital, São Paulo, São Paulo, Brazil

Sarcoma, Gastrointestinal malignancies

Philip A. Philip, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Kenneth Pienta, University of Michigan, Ann Arbor, Michigan, United States

Yotsawat Pomyen, Chulabhorn Research Institute, Bangkok, Thailand

Bioinformatics, Primary Liver Cancer

Karine Pozo, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, Dallas, Texas, United States

Small cell lung cancer, thyroid cancer, neuroendocrine tumors, tumor heterogeneity, signaling pathways, tyrosine kinase inhibitors, cell adhesion, cell surface molecules, [connections between cancer cells and neurons have been discovered recently: neurotransmitter release, neurons]

Guillem Pratx, Stanford University, Stanford, California, United States

Radiation therapy technology; Cancer imaging, mainly nuclear medicine, PET, radiopharmaceuticals; Cancer nanotechnology; In vitro microfluidics assays; Mathematical oncology

Rafael Pulido, Biocruces Bizkaia Health Research Institute, Barakaldo, Spain

Cancer Signal Transduction, Kinases, Phosphatases, Tumor Suppressors, MAP kinase pathways, PTEN

Krishnaraj Rajalingam, Johannes Gutenberg University University Medical Centre, Mainz, Germany

Molecular cell biology

Dayanidhi Raman, University of Toledo - Health Science Campus, Toledo, Ohio, United States
Breast cancer; Chemokine receptors CXCR4, CXCR2 and CCR7; Metastasis; Chemoresistance; LASP1; Breast cancer stemness and stem-like cells; Cancer Cell Motility; eIF4A

**Giridharan Ramsingh**, University of Southern California, Los Angeles, California, United States
Acute Leukemias, Drug Resistance, Leukemia Stem Cells, Industry

**Ofer Reizes**, Cleveland Clinic, Cleveland, Ohio, United States
Breast cancer, ovarian cancer, cancer stem cells, obesity, single cell sequencing, microbiome

**Jun Ren**, MASSACHUSETTS GENERAL HOSP, Boston, Massachusetts, United States
Tumor microenvironment, Cancer immunotherapy, CAR T therapy, Vascular biology

**Laila Ritsma**, Leiden University Medical Center, Leiden, Netherlands
Microscopy, breast cancer, melanoma, metastasis, TGF-b signaling, dormancy

**Benjamin Roche**, Centre for Ecological and Evolutionary Research on Cancer, Montpellier, France
Ecology and evolution of cancer, transmissible cancer, mathematical modeling

**Paulo C. Rodriguez**, H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, Tampa, Florida, United States
Tumor Immunology, Metabolism, Immunotherapy

**Ze’ev Ronai**, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, United States
Cancer biology, signal transduction, UPR, ubiquitin proteasome system

**Dhruvajyoti Roy**, Helio Health, Irvine, California, United States
Cancer diagnostics, Cancer Genomics, Cancer Therapy, Clinical trials, Epigenetics, Liquid Biopsy, Circulating Tumor Cells (CTCs), Cell free nucleic acids, Exosomes, DNA methylation, Next Generation Sequencing (NGS), Translational cancer research, Bio-analytical chemistry, Early detection technology for cancer, Health Care and surveillance for Liver, Lung, Breast and Colorectal cancer, Nanobiotechnology for molecular detection

**Laura Russo**, University of Milan–Bicocca, Milano, Italy
Bioresorganic chemistry, glycoscience, biomaterials for tissue engineering and 3D printing

**Celeste Sánchez-Romero**, University of the Republic Uruguay, Montevideo, Uruguay
Oral and maxillofacial pathology, molecular pathology, head and neck cancers

**Satyaki Sengupta**, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Transcriptional regulation in cancer, cancer epigenetics, regulation of anti-tumor immune response, MYC/MYCN-driven cancers, pediatric neuroblastoma, RB-E2F tumor suppressor pathway

**Yaqin Shi**, First Affiliated Hospital of Soochow University, Suzhou, China
Targeted therapy and combination therapy of triple negative breast cancer

**Anthony Shields**, Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
GI cancers, pancreatic cancer, biliary cancers, cholangiocarcinoma, gallbladder cancer, biomarkers, translational research, immunotherapy

**Rajesh Sinha**, The University of Alabama, Tuscaloosa, Alabama, United States
Molecular Biology, Cancer Biomarker, Infectious diseases, Drug development

**Karel Smetana, Jr.**, Charles University First Faculty of Medicine, Czech Republic
Tumour microenvironment

**Maria Soledad Sosa**, Icahn School of Medicine at Mount Sinai, New York, New York, United States
Dormancy, cancer metastasis, dissemination, residual disease

**Izabela Sumara**, Institut of Genetics and Molecular and Cellular Biology, Illkirch Graffenstaden, France
Cell division and ubiquitin

**Moshe Talpaz**, University of Michigan, Ann Arbor, Michigan, United States
Cancer genetics and epigenetics, biomarkers

**Randall K Ten Haken**, University of Michigan, Ann Arbor, Michigan, United States
Head and Neck cancers, miRNA gene regulation, miRNA diagnostics, HPV16 cancers and virology, salivary biomarkers for cancer detection

**Hery Urra**, Biomedical Neuroscience Institute, Santiago, Chile
Brain cancer, Melanoma, ER stress, Unfolded protein Response, Invasion, Cell migration, Metastasis

**Ilya Ulasov**, I M Sechenov First Moscow State Medical University Institute of Regenerative Medicine, Moskva, Russian Federation
Gene therapy, neuro-oncology, glioblastoma, brain metastases, cell death, autophagy

**Maruti Chandra Uppalapati**, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
Protein engineering, Antibody engineering, Phage display

**Louis Vermeulen**, VU University Medical Centre Amsterdam, Amsterdam, Netherlands
Brain cancer, Melanoma, ER stress, Unfolded protein Response, Invasion, Cell migration, Metastasis
Molecular oncology, translational oncology, stem cells, cancer heterogeneity, colorectal cancer  
**Siniša Volarević**, University of Rijeka, Rijeka, Croatia  
Ribosome biogenesis and cancer, cell growth, p53  
**Konstantinos Voskarides**, University of Cyprus, Lefkosia, Cyprus  
Evolutionary theory and cancer, Cancer Genetics, Cancer epidemiology  
**David J. Waxman**, Boston University, Boston, Massachusetts, United States  
P450 metabolism of anticancer drugs, Metronomic chemotherapy, Immunogenic chemotherapy  
**Ralph Weischebaum**, University of Chicago, Chicago, Illinois, United States  
**Christopher Willett**, Duke University School of Medicine, Durham, North Carolina, United States  
**Terence Williams**, OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER, Columbus, Ohio, United States  
**Lee H Wong**, Monash University, Clayton, Victoria, Australia  
Chromatin, histone variants, telomeres, centromeres, ATRX, Epigenetics  
**Jing Wu**, National Cancer Institute, Bethesda, Maryland, United States  
Neuro-Oncology  
**Syn Yeo**, University of Cincinnati, Cincinnati, Ohio, United States  
Breast Cancer Stem Cells, Autophagy  
**Wang Yu**, National Cancer Centre Singapore, Singapore, Singapore  
biomarkers, recurrence, personalized treatment  
**Lianjun Zhang**, Chinese Academy of Medical Sciences Suzhou Institute of Systems Medicine, Suzhou, China  
Tumor immunology and immunotherapy, tumor microenvironment, cancer metabolism and immunometabolism  
**Weijie Zhang**, Baylor College of Medicine Lester and Sue Smith Breast Center, Houston, Texas, United States  
Breast Cancer Oncogenesis, Cancer Metastasis  
**Zhao Zhang**, The University of Texas Health Science Center at Houston, Houston, Texas, United States  
Bioinformatics, Cancer genomics, non-coding RNA, gene regulation  
**Zijian Zhang**, Baylor College of Medicine, Houston, Texas, United States  
Cancer Epigenetics and Drug Discovery  
**Hengbo Zhou**, MASSACHUSETTS GENERAL HOSPITAL, Boston, Massachusetts, United States  
Tumor immunology, EMT and metastasis
GUIDE FOR AUTHORS

Your Paper Your Way
We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article. To find out more, please visit the Preparation section below.

Scope and Mission
Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

Peer Review
This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. More information on types of peer review.

The Editors are committed to a rapid review process with high quality standards. Every effort will be made to obtain reviews and return editorial decisions to the authors within 3 weeks of manuscript receipt. When manuscripts are accepted contingent on revision, the revised work must be received within three weeks of the decision date, unless prior arrangements are made with the Editors.

Guidelines for Editorial Decisions
The primary criteria for judging which manuscripts are published are originality and scientific/clinical significance. Manuscripts may be editorially declined on these grounds, even if the experimental work appears technically sound.

Prior Publication
The submitted material must not be published nor submitted elsewhere, except in abstract form.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information pages on Ethics in publishing and Ethical guidelines for journal publication.

Studies in humans and animals
If the work involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. The manuscript should be in line with the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals and aim for the inclusion of representative human populations (sex, age and ethnicity) as per those recommendations. The terms sex and gender should be used correctly.

Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

All animal experiments should comply with the ARRIVE guidelines and should be carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, EU Directive 2010/63/EU for animal experiments, or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978) and the authors should clearly indicate in the manuscript that such guidelines have been followed. The sex of animals must be indicated, and where appropriate, the influence (or association) of sex on the results of the study.
Informed consent and patient details

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in the paper. Appropriate consents, permissions and releases must be obtained where an author wishes to include case details or other personal information or images of patients and any other individuals in an Elsevier publication. Written consents must be retained by the author but copies should not be provided to the journal. Only if specifically requested by the journal in exceptional circumstances (for example if a legal issue arises) the author must provide copies of the consents or evidence that such consents have been obtained. For more information, please review the Elsevier Policy on the Use of Images or Personal Information of Patients or other Individuals. Unless you have written permission from the patient (or, where applicable, the next of kin), the personal details of any patient included in any part of the article and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Declaration of interest

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

Submission declaration and verification

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see 'Multiple, redundant or concurrent publication' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.

Preprints

Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Use of inclusive language

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns (“clinicians, patients/clients”) as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Author contributions

For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. More details and an example
**Authorship**
When submitting a paper authors must complete the Authorship form, download from here. This form confirms that all authors agree to publication if the paper is accepted and allows authors to declare any conflicts of interest, sources of funding and ethical approval (if required). Please download the form and submit it with your paper. Submissions that do not include a completed form will be returned without review.

**Changes to authorship**
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed.

Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

**Article transfer service**
This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. More information.

**Copyright**
Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' (see more information on this). Permitted third party reuse of open access articles is determined by the author's choice of user license.

**Author rights**
As an author you (or your employer or institution) have certain rights to reuse your work. More information.

**Sequence Data**
GenBank/EMBL/DDBJ database accession numbers are required for all new sequences before they can be published in Translational Oncology. Sequence data should be sent to GenBank before the manuscript is submitted for review. If the number is not available at the time of submission, it can be added at the page-proof stage.

Elsevier supports responsible sharing Find out how you can share your research published in Elsevier journals.

**Role of the funding source**
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

**Open access**
Please visit our Open Access page for more information.

**Language (usage and editing services)**
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service available from Elsevier's WebShop. Please note the journal also offers complimentary language editing at the discretion of the editor.
**Submission**
Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor’s decision and requests for revision, is sent by e-mail.

*Submit your article*

**PREPARATION**

**NEW SUBMISSIONS**
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

**References**
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

**Formatting requirements**
There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

**REVISED SUBMISSIONS**

**Use of word processing software**
Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

**Article structure**

**Subdivision - unnumbered sections**
Divide your article into clearly defined sections. Each subsection is given a brief heading. Each heading should appear on its own separate line. Subsections should be used as much as possible when cross-referencing text: refer to the subsection by heading as opposed to simply 'the text'.

**Introduction**
State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.
Material and methods
Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

Results
Results should be clear and concise.

Discussion
This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.

Conclusions
The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

Essential title page information

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

Twitter handle
If you would like your Twitter handle to be included on your published paper, please provide it on your title page.

Abstract
A concise and factual abstract is required not exceeding 250 words. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

Keywords
Immediately after the abstract, provide a maximum of 6 keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, 'and', 'of'). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

Abbreviations
Define abbreviations that are not standard in this field in a footnote to be placed on the first page of the article. Such abbreviations that are unavoidable in the abstract must be defined at their first mention there, as well as in the footnote. Ensure consistency of abbreviations throughout the article.

Acknowledgements
Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).
Formatting of funding sources
List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Units
Follow internationally accepted rules and conventions: use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

Footnotes
Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors build footnotes into the text, and this feature may be used. Should this not be the case, indicate the position of footnotes in the text and present the footnotes themselves separately at the end of the article.

Artwork
Electronic artwork
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• For Word submissions only, you may still provide figures and their captions, and tables within a single file at the revision stage.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.

A detailed guide on electronic artwork is available.

You are urged to visit this site; some excerpts from the detailed information are given here.

Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics'.
TIFF (or JPEG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPEG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPEG): Combinations bitmapped line/halftone (color or grayscale): a minimum of 500 dpi is required.

Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.

Illustration services
Elsevier's Author Services offers Illustration Services to authors preparing to submit a manuscript but concerned about the quality of the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also available, where our illustrators take your image(s) and improve them to a professional standard. Please visit the website to find out more.
Figure captions
Ensure that each illustration has a caption. A caption should comprise a brief title (not on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

Tables
Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

References
Citation in text
Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with either 'Unpublished results' or 'Personal communication'. Citation of a reference as 'in press' implies that the item has been accepted for publication.

Reference links
Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the Lesser Antilles slab beneath northeastern Venezuela. Journal of Geophysical Research, https://doi.org/10.1029/2001JB000884. Please note the format of such citations should be in the same style as all other references in the paper.

Web references
As a minimum, the full URL should be given and the date when the reference was last accessed. Any further information, if known (DOI, author names, dates, reference to a source publication, etc.), should also be given. Web references can be listed separately (e.g., after the reference list) under a different heading if desired, or can be included in the reference list.

Data references
This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

References in a special issue
Please ensure that the words 'this issue' are added to any references in the list (and any citations in the text) to other articles in the same Special Issue.

Reference formatting
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct. If you do wish to format the references yourself they should be arranged according to the following examples:

*Journal abbreviations source*
Journal names should be abbreviated according to the List of Title Word Abbreviations.
**Video**
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file’s content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply ‘stills’ with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Data visualization**
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplementary material**
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**
If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).
Mendeley Data
This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

Data statement
To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

Submission Checklist
The following list will be useful during the final checking of an article prior to sending it to the journal for review. Please consult this Guide for Authors for further details of any item.

Ensure that the following items are present:
Authors understand they will be responsible for paying the publication fee if the submission is accepted.

One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
• Phone numbers

All necessary files have been uploaded, and contain:
• Keywords
• All figure captions
• All tables (including title, description, footnotes)

Further considerations
• Manuscript has been 'spell-checked' and 'grammar-checked'
• All references mentioned in the Reference list are cited in the text, and vice versa
• Permission has been obtained for use of copyrighted material from other sources (including the Web)

For any further information please visit our customer support site at https://service.elsevier.com.

AFTER ACCEPTANCE

Online proof correction
To ensure a fast publication process of the article, we kindly ask authors to provide us with their proof corrections within two days. Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors.

If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will be notified and receive a link to the published version of the open access article on ScienceDirect. This link is in the form of an article DOI link which can be shared via email and social networks. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier’s Author Services.
AUTHOR INQUIRIES
Visit the Elsevier Support Center to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.
You can also check the status of your submitted article or find out when your accepted article will be published.

© Copyright 2018 Elsevier | https://www.elsevier.com